Abstract: The present invention discloses a sanguisorbigenin polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 30 parts of sanguisorbigenin and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of sanguisorbigenin polymer micelle prepared is the best, and using other materials can lead to the lowered preparation quality. In pharmacodynamic experiment, compared with the model group, the sanguisorbigenin micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug of sanguisorbigenin, indicating the sanguisorbigenin polymer micelle has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug of sanguisorbigenin.

Abstract: The present invention provides methods for treating conditions that involve infection and/or inflammation, including acute and chronic inflammation, as well as delayed-type and immediate-type hypersensitivity. The invention in various embodiments provides methods for treating microbial infection and the associated inflammatory response, as well methods for treating inflammatory conditions that spawn or are susceptible to secondary microbial infection. Further, the invention provides methods for treating inflammation, such as chronic inflammation, without any associated microbial infection.

Abstract: The present invention relates to microencapsulation technology and specifically, nitrite salt microencapsulation and uses of microencapsulated nitrite in the manufacture of animal pest baits, especially baits to be used in humane methods for controlling feral pig and possum populations.

Abstract: The present invention in various aspects and embodiments provides methods and formulations for treating inflammatory conditions of the skin and/or conditions involving compromised skin barrier function. Such diseases include blistering diseases of the skin, hereditary defects in skin barrier function, hyperproliferative conditions involving the skin, conditions associated with aging or damaged skin, immunological disorders involving the skin, among others.

Abstract: The present invention relates to an orally administrable pharmaceutical dosage form for use in the prevention and/or treatment of a cardiovascular disease which includes (a) acetylsalicylic acid as a first active agent and (b) HMG-CoA reductase inhibitor as a second active agent. The HMG-CoA reductase inhibitor is selected from atorvastatin and rosuvastatin and salts thereof. The present invention is formulated in (a) two or more single separate coated dosage units in which the coating includes one or more water-soluble polymer and no more than 0 to 5% by weight of the coating of water-insoluble or enteric polymer, and in which the dosage units include 8 to 12 mg/cm2 coating and show an immediate release profile; and (b) one or more single separate coated dosage units.

Abstract: Disclosed is a topical skin care formulation comprising water, kaolin, glycerin, lactobacillus ferment, Helianthus annuus seed extract, and Terminalia ferdinandiana fruit extract.

Abstract: Provided is a hydrogel. The hydrogel includes a liquid and a plurality of microfibers suspended in the liquid as an entangled network. The entangled network includes physically entangled microfibers that are mechanically interlocked.

Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Abstract: The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.

Abstract: Carotenoid compositions are described for management, treatment, and/or prevention of stress by reducing cortisol levels and/or improving distribution and/or density of macular pigment and thus improving overall health status. More particularly, a subject in need thereof for the method has disturbed macular pigment optical density or increased levels of cortisol as markers of psychological and physiological stress. Methods are also described of administering macular carotenoid compositions in daily doses of at least or about 0.005 mg/kg body weight of lutein, and at least or about 0.001 mg/kg body weight of meso-zeaxanthin and zeaxanthin isomer along with at least one food grade excipient and evaluating overall health status. The composition may be derived from plant extract containing xanthophylls and/or xanthophylls esters. The composition also reduces cortisol levels in the blood and relieves physiological stress, thus improving overall health status of a subject in need thereof.

Abstract: A treatment device for a beehive includes a strip having at least one layer. The at least one layer is formed from a biodegradable material permeable to water, such as paper. At least one layer is saturated with a treatment fluid. A reinforcement or join is provided to or adjacent each longitudinal edge of the strip, to protect and/or reinforce the longitudinal edges to mechanically resist attack by bees in the hive.

Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Abstract: This document provides methods and materials related to treating cancer. For example, methods and materials for using particles (e.g., nanoparticles) containing (a) one or more molecules having the ability to bind to a cancer cell (e.g., a human breast cancer cell) and (b) one or more molecules having the ability to bind to an APC (e.g., a human macrophage) to treat cancer are provided.

Abstract: The present invention relates to pesticidal mixtures. In particular it relates to mixtures of loline alkaloids with other pesticides. Such mixtures are useful for the control of insect pests and for improving the yield of crop plants.

Abstract: Natural haircare ingredient composition and haircare compositions containing such natural haircare ingredient compositions are provided. In one novel aspect, the natural hair ingredient composition is provided which comprises candida Krusei mediated bio-modification of marine organism and plants including bio-modified natural marine surfactants, three-dimensional molecular framework, and natural mineral salts. In one embodiment, the natural surfactants are produced from natural marine organisms such as brown algae, sea kelp, sponge, brown seaweeds, and red seaweeds by candida Krusei mediated bio-modification. In another novel aspect, a haircare composition comprises about 10% of the natural haircare ingredient composition, by weight of the haircare composition. In one novel aspect, Candida Krusei bio-modification process is used. Natural polymeric compounds in the marine plants are modified during the process resulting in three-dimensional molecular framework.

Abstract: Provided is a powder containing ferric pyrophosphate that affords high iron absorbability, as a main component of an oral iron preparation. The present invention relates to a composite powder containing ferric pyrophosphate, which is a powder containing ferric pyrophosphate and a sodium component, wherein (1) the content of ferric pyrophosphate is 95 wt % or higher, and (2) a (Fe+Na)/P molar ratio is 0.8 to 1.0.

Abstract: A dosage form article consisting of a hard capsule coated with a surface modifying coating wherein the coating is an aqueous composition comprising water and a muco-adhesive polymer selected from the group consisting of poly(acrylates), cellulose derivatives, hyaluronic acid, starch, poly(ethylene glycol), polysaccharides, collagen derivatives, and mixtures thereof, wherein the ratio of the muco-adhesive polymer to water is less than 0.15 by weight of the coating composition.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating breast cancer which includes tetraarsenic hexoxide in which a crystalline polymorph a(As4O6-a), of tetraarsenic hexoxide is 99% or higher, and to a method for producing the same. The composition of the present invention exhibits excellent effects of inhibiting the proliferation and metastasis of cancer cells, and thus can be usefully used as an anticancer agent.

Abstract: The present invention relates to a dispensing device comprising: a) a container comprising a deformable wall, and b) a composition stored in the container, and comprising, in a cosmetically acceptable medium: i) at least one aqueous phase, and ii) optionally at least one oily phase, iii) at least one structuring agent; the said composition having a stiffness modulus G*>5000 Pa, and c) a dispensing head closing off the container and comprising an application wall defining at least one product dispensing orifice which is a slit. The present invention also relates to a cosmetic process for treating and/or caring for human keratin materials, characterized in that it consists in applying to the surface of the keratin material a composition dispensed via the device as defined previously.

Abstract: The present disclosure relates to hydrogels and their use for repairing or supplementing body tissue. The hydrogels are capable of safe injection into patients through fine gauge needles and are suitable for repairing or supplementing the nucleus pulposus of an intervertebral disc. Methods of manufacturing and methods of using the hydrogels of the present disclosure to repair or replace tissues are also disclosed.